CMS Banned Federal Funding for Pediatric Gender Care
The new rule stops Medicaid and CHIP from paying for gender-affirming procedures for minors in the United States.
Updated on Oct. 13, 2026 in Children’s Health
Live Poll
Should federal Medicaid and CHIP funds cover gender-affirming medical treatments for children?
The Centers for Medicare & Medicaid Services has prohibited federal funding for sex-rejecting procedures for individuals under 18 and 19. The policy excludes treatments for disorders of sexual development and precocious puberty while allowing mental health services to remain covered.
Why it matters
Federal officials stated the decision follows an assessment that the evidence supporting the benefits of these pediatric gender interventions is of very low quality. The regulation restricts federal financial participation rather than dictating the practice of medicine itself.
In 2023, Medicaid and CHIP spending for hormone therapy totaled $23.8 million, with 88% of those funds attributed specifically to puberty blockers. CMS officials estimate the new prohibition will reduce total program spending by $235 million from fiscal year 2027 through 2036.
The players
Centers for Medicare & Medicaid Services
This federal agency within the United States Department of Health and Human Services administers the Medicaid and Children’s Health Insurance Program.
The details
Providers may still bill Medicaid and CHIP for procedures if they are utilized for non-gender-affirming medical purposes. While over 90% of the 11,000 public comments submitted during the proposal phase opposed the change, the agency finalized the rule to limit federal backing for these interventions.
Timeline
Spending data for hormone therapy was collected throughout 2023.
The proposed rule was first published on December 19, 2025.
The rule took effect on October 13, 2026.
The six-month tapering period for current patients ends in April 2027.
Spending reductions are projected through the end of fiscal year 2036.
Health Landscape
This decision mirrors clinical policy shifts observed in the United Kingdom, Sweden, and Finland, which have recently restricted pediatric gender-affirming interventions due to concerns over evidence quality. The move marks a departure from previous federal coverage standards for these medical services in the United States.
Families relying on Medicaid or CHIP for gender-affirming care will no longer receive federal funding for these specific procedures as of October 13, 2026. Current patients have a six-month tapering window for hormone therapy, though non-gender-affirming medical treatments remain covered.
The takeaway
The federal government has transitioned its stance on pediatric gender interventions by prioritizing evidence-based funding restrictions for Medicaid and CHIP. Patients affected by this change should consult with their healthcare providers regarding the tapering process and alternative coverage options.
What happens next
A six-month tapering period for children currently receiving cross-sex hormone therapy will conclude in April 2027.
Further reading
For additional context on healthcare standards for minors, visit the Children’s Health section.
More information
Review the Final federal rule on Medicaid funding for specific details.
Live Poll
Should federal Medicaid and CHIP funds cover gender-affirming medical treatments for children?
